RNS Number : 1092H
  Osmetech PLC
  31 October 2008
   


    31 October 2008        
            
    Osmetech plc ('Osmetech' or the 'Company')

    Warfarin Sensitivity study results 
    Update on proposed issue of American Depositary Shares

    Osmetech plc (OMH.L), the international molecular diagnostics company announces that Dr. Charles S. Eby, M.D., Associate Professor at
the Washington University in St. Louis School of Medicine has presented the results of an evaluation performed in his laboratory of
Osmetech's Warfarin Sensitivity Test on the eSensor� XT-8 instrument at the annual meeting of the Association for Molecular Pathology (AMP)
in Texas, US. The results of this evaluation were outstanding, with 100% accuracy and reproducibility for the 440 sample calls made. The
tests provided results within 4 hours beginning with genomic DNA, with the random access capability of the System allowing multiple samples
to be processed as and when required. 

    Dr. Eby also presented an overview of pharmacogenetic testing for warfarin sensitivity, including plans for a prospective, multi-center
study of pharmacogenetic-based warfarin dosing sponsored by the National Heart, Lung and Blood Institute.

    James White, Chief Executive, Osmetech plc, said:
    "We are delighted that the excellent clinical trials results submitted to the FDA for the clearance of our Warfarin Sensitivity test are
being replicated in the field. In addition to high levels of accuracy, sensitivity and reliability from the results from Dr Eby's study, the
eSensor XT-8 System has enabled testing to be performed with a minimal number of manual steps and a rapid turnaround time on an easy to use,
small instrument with random access capabilities.  The excellent data quality and user friendly attributes of the recently launched eSensor
XT-8 System are helping to increase instrument placements which will benefit further from additional tests scheduled for launch including
Cystic Fibrosis, CYP450 2C9 drug metabolism, venous thrombosis (Factor II, Factor V Leiden and MTHFR) and the recently in-licensed Qiagen
RESPLEX II respiratory pathogen assay."

    Proposed issue of American Depositary Shares ("ADSs")
Osmetech continues to progress the proposed issue of ADSs in challenging market conditions. A further announcement will be made in due
course.

    Warfarin sensitivity test
    Warfarin is the most widely prescribed oral anticoagulant in North America and Europe with an estimated 2 million new patients in the US
each year. Warfarin is the second-most-likely drug, after Digoxin, to cause adverse events requiring hospitalization. A recent economic
study (Brookings Institute, November 2006) concluded that widespread use of warfarin sensitivity testing in the U.S. could avoid 85,000
serious-bleeding events and 17,000 strokes a year, saving healthcare costs of approximately $1.1 billion annually and improving patient
care.

    Our eSensor Warfarin Sensitivity Test detects the three genetic markers that are known to play a critical role in metabolism of, and
sensitivity to, warfarin. Through detection of these genetic markers, doctors are better able accurately and efficiently to determine the
appropriate warfarin dosage level. Individuals respond to warfarin differently, and if its administration is not managed carefully, life
threatening side effects may occur.  Last year, the FDA cleared updated labelling for Coumadin� (generic name warfarin) recognizing the role
of CYP2C9 and VCORC1 genes in warfarin metabolism.

    eSensor XT-8
    Our second generation platform, the eSensor XT-8, is designed to support a broad menu of tests and provide accurate results while
minimizing technician involvement. We believe that the features of our eSensor XT*8 System compare favorably to those of other molecular
detection systems and that its ease of use, readily interpretable results, speed and low maintenance are particularly suited to the needs of
the decentralizing market. 


    Osmetech plc                                      +44 (0)207 849 6027
    James White, Chief Executive Officer
    David Sandilands, Chief Financial Officer

    Madano Partnership                         +44 (0) 207 593 4000
    Matthew Moth, Mark Way
    www.madano.com

    Canacccord Adams Limited            +44 (0) 207 050 6500
    Robert Finlay, Warren Pimm


    About Osmetech plc
    www.osmetech.com


    Osmetech plc is an AIM-listed public company on the London Stock Exchange. The company is a fast developing, international diagnostics
business with operations in Boston and Pasadena in the US, serving the high growth molecular diagnostic market targeting hospitals and
reference laboratories. Osmetech has a strong portfolio of over 200 issued and pending patents and has launched its first generation eSensor
4800 platform, an electrochemistry-based array system, together with an FDA cleared in vitro diagnostic test for Cystic Fibrosis carrier
detection. 



This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
STREADEEDDKPFAE
Osmetech (LSE:OMH)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Osmetech Charts.
Osmetech (LSE:OMH)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Osmetech Charts.